Meeting
2022 ASCO Annual Meeting
Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11).
Authors
Jiyun Lee
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Jiyun Lee , Sehhoon Park , Hyun Ae Jung , Se-Hoon Lee , Seyoung Seo , Sung-Bae Kim , Ji-Won Kim , Keun Wook Lee , Eun Joo Kang , Ju Won Kim , Yoon Ji Choi , Byoung Yong Shim , Ho Jung An , Lee Chun Park , SeongHoon Shin , Jae-Joon Kim , So Yeon Oh , Min Kyoung Kim , Myung-Ju Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03614364
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6018)
DOI
10.1200/JCO.2022.40.16_suppl.6018
Abstract #
6018
Poster Bd #
10
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2018 ASCO Annual Meeting
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
First Author: Nabil F. Saba
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris